Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00034944
NCT00034944
Completed
Phase 3

A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder

Merck Sharp & Dohme LLC0 sites495 target enrollmentJanuary 24, 2002
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMajor Depressive Disorder
DrugsMK0869, aprepitantComparator: placebo

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Major Depressive Disorder
Sponsor
Merck Sharp & Dohme LLC
Enrollment
495
Primary Endpoint
HAMD-17 total score at week 8. Tolerability.
Status
Completed
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Detailed Description

The duration of treatment is 8 weeks.

Registry
clinicaltrials.gov
Start Date
January 24, 2002
End Date
December 17, 2003
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

HAMD-17 total score at week 8. Tolerability.

Secondary Outcomes

  • CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score.

Similar Trials

Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)Major Depressive Disorder
NCT00042029Merck Sharp & Dohme LLC324
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)Major Depressive Disorder
NCT00048607Merck Sharp & Dohme LLC600
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)Major Depressive Disorder
NCT00035009Merck Sharp & Dohme LLC468
Completed
Phase 2
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive DisorderDepressive Disorder, Major
NCT00048204GlaxoSmithKline372
Completed
Phase 3
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)Depressive Disorder, Major
NCT02709655H. Lundbeck A/S683